| Wilson Martin Nino, MD | |
|
201 W Liberty Way, Milford, DE 19963-5399 | |
| (302) 424-3694 | |
| (302) 424-3697 |
| Full Name | Wilson Martin Nino |
|---|---|
| Gender | Male |
| Speciality | Nephrology |
| Experience | 31 Years |
| Location | 201 W Liberty Way, Milford, Delaware |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1396720645 | NPI | - | NPPES |
| 521860379 | Other | COVENTRY | |
| 119591300 | Medicaid | MD | |
| 054635 | Other | JHHC | |
| 7628798 | Other | AETNA | |
| KQ630036 | Other | CAREFIRST |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RN0300X | Internal Medicine - Nephrology | C10010019 (Delaware) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Fresenius Medical Care Milford | Milford, DE | Dialysis facility |
| Fresenius Medical Care Millsboro | Millsboro, DE | Dialysis facility |
| Bayhealth Hospital, Sussex Campus | Milford, DE | Hospital |
| Beebe Medical Center | Lewes, DE | Hospital |
| Nanticoke Memorial Hospital | Seaford, DE | Hospital |
| Bayhealth Hospital, Kent Campus | Dover, DE | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Nephrology Associates Pa | 9830098177 | 56 |
News Archive
Shire plc, the global specialty biopharmaceutical company, announced findings from a post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse®. In this study, Vyvanse demonstrated significant improvement in Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms as measured by the ADHD Rating Scale IV (ADHD-RS IV) and Connors' Parent Rating Scale-Revised Short (CPRS-RS) in children with ADHD aged 6 to 12 years.
The U.S. Food and Drug Administration recently approved the first new drug to fight tuberculosis (TB) in more than 40 years, but treatment still takes six months, 200 pills and leaves 40 percent of patients uncured. Thus, new targets are needed. Today in ACS Central Science, researchers report they have identified one such target - a gene that allows the disease to camp out in human immune cells, and is thus essential for the organism's proliferation.
Health care, unemployment, immigration, and education top a lengthy and varied list of the American public's policy priorities for 2017, according to a new national survey conducted by The Associated Press-NORC Center for Public Affairs Research.
VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced the initiation of two studies to further evaluate the efficacy and safety of VB-111 in advanced cancers.
› Verified 1 days ago
| Entity Name | Nephrology Associates Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407805203 PECOS PAC ID: 9830098177 Enrollment ID: O20040106000439 |
News Archive
Shire plc, the global specialty biopharmaceutical company, announced findings from a post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse®. In this study, Vyvanse demonstrated significant improvement in Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms as measured by the ADHD Rating Scale IV (ADHD-RS IV) and Connors' Parent Rating Scale-Revised Short (CPRS-RS) in children with ADHD aged 6 to 12 years.
The U.S. Food and Drug Administration recently approved the first new drug to fight tuberculosis (TB) in more than 40 years, but treatment still takes six months, 200 pills and leaves 40 percent of patients uncured. Thus, new targets are needed. Today in ACS Central Science, researchers report they have identified one such target - a gene that allows the disease to camp out in human immune cells, and is thus essential for the organism's proliferation.
Health care, unemployment, immigration, and education top a lengthy and varied list of the American public's policy priorities for 2017, according to a new national survey conducted by The Associated Press-NORC Center for Public Affairs Research.
VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced the initiation of two studies to further evaluate the efficacy and safety of VB-111 in advanced cancers.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Wilson Martin Nino, MD 4923 Ogletown Stanton Rd, Suite 200, Newark, DE 19713-2081 Ph: (302) 225-0451 | Wilson Martin Nino, MD 201 W Liberty Way, Milford, DE 19963-5399 Ph: (302) 424-3694 |
News Archive
Shire plc, the global specialty biopharmaceutical company, announced findings from a post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse®. In this study, Vyvanse demonstrated significant improvement in Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms as measured by the ADHD Rating Scale IV (ADHD-RS IV) and Connors' Parent Rating Scale-Revised Short (CPRS-RS) in children with ADHD aged 6 to 12 years.
The U.S. Food and Drug Administration recently approved the first new drug to fight tuberculosis (TB) in more than 40 years, but treatment still takes six months, 200 pills and leaves 40 percent of patients uncured. Thus, new targets are needed. Today in ACS Central Science, researchers report they have identified one such target - a gene that allows the disease to camp out in human immune cells, and is thus essential for the organism's proliferation.
Health care, unemployment, immigration, and education top a lengthy and varied list of the American public's policy priorities for 2017, according to a new national survey conducted by The Associated Press-NORC Center for Public Affairs Research.
VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced the initiation of two studies to further evaluate the efficacy and safety of VB-111 in advanced cancers.
› Verified 1 days ago
Antonio L Zarraga, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 101 Wellness Way Ste 200, Milford, DE 19963 Phone: 302-430-0867 Fax: 302-430-0421 | |
Rabail Qureshi, M.D Nephrology Medicare: Accepting Medicare Assignments Practice Location: 201 W Liberty Way, Milford, DE 19963 Phone: 302-424-3694 | |
Maryam Munir, MD Nephrology Medicare: Medicare Enrolled Practice Location: 100 Wellness Way, Milford, DE 19963 Phone: 347-325-0762 | |
Ethan Frederick Keller, MD Nephrology Medicare: Medicare Enrolled Practice Location: 804 N Dupont Blvd, Milford, DE 19963 Phone: 302-725-3557 | |
Meliseanna Katerina Elizabeth Gibbons, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 101 Wellness Way Ste 200, Milford, DE 19963 Phone: 302-430-0867 Fax: 302-430-0421 | |
Shilpa Odedra, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 100 Wellness Way, Milford, DE 19963 Phone: 302-430-5175 | |
Dr. Vikrant R Agrawal, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 100 Wellness Way, Milford, DE 19963 Phone: 302-430-5175 |